Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.03, for a total value of $27,637.58. Following the sale, the insider now owns 80,818 shares in the company, valued at $2,265,328.54. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Castle Biosciences Trading Up 0.3 %

Castle Biosciences stock opened at $25.09 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The firm’s 50-day moving average is $29.40 and its 200-day moving average is $28.00. The company has a market cap of $702.77 million, a P/E ratio of 125.46 and a beta of 0.92.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million for the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same quarter last year, the company posted ($0.26) earnings per share. On average, equities analysts expect that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CSTL. Algert Global LLC lifted its stake in Castle Biosciences by 0.4% in the third quarter. Algert Global LLC now owns 134,321 shares of the company’s stock valued at $3,831,000 after buying an additional 599 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Castle Biosciences by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after acquiring an additional 675 shares during the period. Assetmark Inc. lifted its position in Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after purchasing an additional 748 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its stake in Castle Biosciences by 3.6% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company’s stock valued at $690,000 after purchasing an additional 845 shares during the period. Finally, Quest Partners LLC grew its position in Castle Biosciences by 54.4% in the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after purchasing an additional 1,522 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on CSTL shares. BTIG Research raised their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Canaccord Genuity Group raised their price objective on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Robert W. Baird upped their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Finally, KeyCorp boosted their price objective on Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences currently has an average rating of “Buy” and a consensus target price of $40.29.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.